
Axent Biosciences Axent Biosciences is a pre-clinical stage company that aims to revolutionize the field of cell therapy by leveraging a simple, safe and scalable cell cultivation technology to produce most-in-class stem cell-derived therapies that maintain the highest quality standards. Axent’s platform utilizes a novel, biomimetic 3D matrix that supports robust cell growth and differentiation while enabling commercial-scale production. This platform addresses major limitations in current stem cell manufacturing, including genomic stability, scalability, yield, and reproducibility, by providing a consistent and shear-protected environment that is compatible will multiple bioreactor configurations and scales. Cells produced in Axent’s system exhibit high viability, genomic stability over 60+ doublings, and superior potency. Moreover, the system demonstrates compatibility with standard differentiation media and produces significantly higher cell yields than traditional 2D or 3D suspension cultures, unlocking commercial-scale production for indications requiring large cell numbers such as Type 1 Diabetes, Liver and Heart Failure. Therapeutic Developer

Axent Biosciences

Axent Biosciences is a pre-clinical stage company that aims to revolutionize the field of cell therapy by leveraging a simple, safe and scalable cell cultivation technology to produce most-in-class stem cell-derived therapies that maintain the highest quality standards. Axent’s platform utilizes a novel, biomimetic 3D matrix that supports robust cell growth and differentiation while enabling commercial-scale production. This platform addresses major limitations in current stem cell manufacturing, including genomic stability, scalability, yield, and reproducibility, by providing a consistent and shear-protected environment that is compatible will multiple bioreactor configurations and scales. Cells produced in Axent’s system exhibit high viability, genomic stability over 60+ doublings, and superior potency. Moreover, the system demonstrates compatibility with standard differentiation media and produces significantly higher cell yields than traditional 2D or 3D suspension cultures, unlocking commercial-scale production for indications requiring large cell numbers such as Type 1 Diabetes, Liver and Heart Failure.

Therapeutic Developer